Sino Biopharmaceuticals (01177.HK) announced on March 6 that the company recently reached an exclusive cooperation agreement with Nanjing Qingpu Biotechnology Co., Ltd. (hereinafter referred to as "Qingpu Biotechnology") in mainland China for its developed national Class 2 new drug QP001.

According to reports, QP001 is a meloxicam injection registered as a national Class 2 new drug. It is a long-acting, potent new non-steroidal anti-inflammatory drug (NSAIDs) for postoperative pain. Compared with traditional non-selective NSAIDs, QP001 is a selective cyclooxygenase-2 (COX-2) inhibitor that can block the release of COX-2 that causes body pain and inflammation, reduce or block the synthesis of prostaglandins (PGs) in the affected area, thereby playing an anti-inflammatory and analgesic role, while having little effect on cyclooxygenase-1 (COX-1) that maintains normal physiological functions. Therefore, in the future, patients with mild renal impairment, elderly patients and other special groups can also use it normally.

China Biopharmaceuticals said that at present, there is no meloxicam injection for the treatment of postoperative pain in China. Data show that postoperative pain is one of the most common acute pains in clinical practice, but the current popularity of postoperative analgesia in China is low, and there is a huge clinical demand.

Surgery/analgesia is one of the four major therapeutic areas of China Biopharmaceuticals. China Biopharmaceuticals said that QP001 is expected to take over from flurbiprofen axetil injection and become another blockbuster product in the field of analgesia.

https://finance.eastmoney.com/a/202503073340011482.html